Pacific Edge Limited

Pacific Edge Limited, based in New Zealand, focuses on cancer diagnostics with a suite of bladder cancer diagnostic tools using genetic biomarkers. The company operates with a head office in Dunedin, New Zealand, and also has an office in Hershey, USA. It is listed on the New Zealand NZX main board stock exchange and is included in the NZX 50 Index.^[3]

Pacific Edge Limited

Company type	Public
Traded as	NZX: PEB
Industry	Cancer diagnostics
Founded	2001
Headquarters	Dunedin, New Zealand and Hershey, USA
Area served	New Zealand, Australia, Spain, United States of America
Key people	David Darling[1][2] (Group CEO) and Jackie Walker (CEO of Pacific Edge Diagnostics USA)
Products	CxBladder Suite of bladder cancer diagnostics tools
Services	Urology
Revenue	$4m as at November 2015
Number of employees	Approx 50 globally
Website	pacificedgedx.com

History

Pacific Edge, founded in August 2001,^[4] utilizes genetic biomarkers in urine for cancer detection. Their approach is positioned as cost-effective compared to other diagnostic methods.^[5] The company offers diagnostic services in New Zealand and the United States and has partnerships in Europe and Australia.

Listed on the New Zealand NZX index, Pacific Edge has undertaken capital raising initiatives, with rounds in 2013 and 2015 aimed at advancing the commercialization of their diagnostic tests in the United States.^[6] In June 2020, Pacific Edge secured a commercial relationship with Kaiser Permanente, one of the largest health insurance providers in the U.S., for its bladder cancer tests.^[7]

Products

Pacific Edge offers a series of bladder cancer diagnostic tests known as CxBladder. These tests include specialist subtype products designed for the detection of cancerous cells and to aid clinicians and oncologists in triage.^[8] The tests are based on non-invasive urine samples, utilizing RNA and protein assays. CxBladder is noted for its sensitivity and potential for earlier detection of bladder cancer, compared to other diagnostic methods such as cytology.^{[9][10][11][12][13][14]}

Awards

Pacific Edge has won a number of awards, including:

• The NZ Innovators Award 2013
• NZBIO Biotech company of the year award 2014
• Medical Technology Association of New Zealand Innovation Award 2016

References

1. "PEB.NZ Profile - Pacific Edge Limited Ordinary S Stock - Yahoo! Finance". Yahoo! Finance. Retrieved 31 December 2015.
2. "Pacific Edge first-half loss widens". The New Zealand Herald. Retrieved 31 December 2015.
3. "Pacific Edge Limited". Retrieved 31 December 2015.
4. "NZX Main Board - PEB Analysis". NZX. Retrieved 31 December 2015. Pacific Edge Limited (PEB) was formed in August 2001 following acquisition of intellectual property from the University of Otago.
5. "Pacific Edge shares soar to new high". New Zealand Herald. 22 October 2013. ISSN 1170-0777. Retrieved 31 December 2015.
6. "Pacific Edge seeks $35.3M to fund US growth". The New Zealand Herald. Retrieved 31 December 2015.
7. "Kaiser Permanente Approves Commercial Use of Cxbladder - NZX, New Zealand's Exchange". www.nzx.com. Retrieved 25 June 2020.
8. "Suite of cancer products grows". Otago Daily Times. 29 December 2015. Retrieved 31 December 2015.
9. Alan Wood (27 May 2015). "Pacific Edge's FY loss widens to $10.58m, plans to raise $35.3m". Stuff.co.nz. Retrieved 31 December 2015.
10. Janis C. Kelly (26 October 2015). "Urinary Biomarkers Not Useful for Bladder Cancer Diagnosis". Medscape. Retrieved 31 December 2015.
11. MARTA STEEMAN (9 June 2015). "Singapore hospital to trial Pacific Edge's main bladder cancer detection product". Stuff.co.nz. Retrieved 31 December 2015.
12. "Warning over bladder cancer test". Stuff.co.nz. 11 July 2014. Retrieved 31 December 2015.
13. "Pacific Edge sales up; still no profit". Otago Daily Times. 27 November 2015. Retrieved 31 December 2015.
14. "Pacific Edge gets US approval for Dunedin laboratory". The New Zealand Herald. Retrieved 31 December 2015.

External links

• Official site